Novabay Pharmaceuticals, INC 8-K filings

Stablecoin Development Corporation reported Q2 2026 results, highlighting $2.2 million in staking revenue and a significant unrealized loss on digital assets, while growing its SKY token holdings.

Stablecoin Development Corporation announced the appointment of Henry Blynn as Chief Operating Officer and set Michael Kazley's CEO salary for 2027.

Stablecoin Development Corporation amended pre-funded warrants with R01 Fund LP and Framework Ventures IV L.P., leading to the issuance of over 22.6 million shares.

Stablecoin Development Corporation reported first quarter 2026 operating income of $22.3 million and GAAP net income of $552.4 million, significantly boosted by non-cash warrant-related gains.

Stablecoin Development Corporation announced that its previously issued 2025 financial statements must be reissued due to an accounting error related to pre-funded warrants.

Stablecoin Development Corporation, formerly NovaBay Pharmaceuticals, has officially rebranded and reported holding 2.15 billion SKY tokens.

NovaBay Pharmaceuticals, Inc. is changing its name to Stablecoin Development Corporation, effective April 2, 2026, and has approved a new equity incentive plan with significant performance-based awards for its CEO.

NovaBay Pharmaceuticals, Inc. announced its rebranding to Stablecoin Development Corporation, a strategic shift into digital assets with a $134 million investment and significant SKY token holdings.

NovaBay Pharmaceuticals, Inc. filed an amended certificate of incorporation and approved key governance changes and share issuances at a special stockholder meeting.

NovaBay Pharmaceuticals will implement a 1-for-5 reverse stock split to meet NYSE American listing requirements, effective February 20, 2026.

NovaBay Pharmaceuticals, Inc. announced the engagement of CBIZ CPAs as its new auditor and scheduled a special stockholder meeting to vote on common stock issuance related to pre-funded warrants.

NovaBay Pharmaceuticals announces its long-standing auditor, WithumSmith+Brown, PC, will not stand for re-appointment as the company pursues dissolution.

NovaBay Pharmaceuticals, Inc. has established an At-The-Market (ATM) sales agreement with Virtu Americas LLC, allowing it to sell up to $100 million of common stock.

NovaBay Pharmaceuticals, Inc. announced a $134 million private placement of pre-funded warrants, signaling a strategic shift towards acquiring and holding revenue-generating digital assets, primarily SKY tokens.

NovaBay Pharmaceuticals, Inc. has filed a Certificate of Designation for its new Series E Non-Voting Convertible Preferred Stock, outlining terms for up to 268,750 shares.

NovaBay Pharmaceuticals, Inc. announced it has regained compliance with the NYSE American's continued listing standards by increasing its stockholders' equity above the $6 million minimum.

NovaBay Pharmaceuticals announced a change of control with R01 Fund LP and Framework Ventures IV L.P. becoming majority owners, alongside a new CEO appointment and significant equity transactions.

NovaBay Pharmaceuticals' CEO, David Lazar, resigned as a significant stake, representing approximately 90% of common stock, is being transferred to R01 Fund LP and Framework Ventures IV L.P.

NovaBay Pharmaceuticals provides crucial details on its $0.80 special cash dividend and upcoming 2025 Annual Meeting of Stockholders, including due bill procedures.

NovaBay Pharmaceuticals announced a $0.80 per share special cash dividend and detailed a $6.0 million investment from CEO David Lazar, following an asset sale.

NovaBay Pharmaceuticals has secured a $6 million investment from David E. Lazar, appointing him CEO and pivoting from potential liquidation to a new strategic acquisition path, alongside a planned special cash dividend for stockholders.

NovaBay Pharmaceuticals' stockholders have approved a plan to liquidate and dissolve the company at a special meeting held on April 16, 2025.

NovaBay Pharmaceuticals has reached settlement agreements with Sabby Volatility Warrant Master Fund, Bigger Capital Fund, and District 2 Capital Fund to resolve disputes related to warrant buyout rights and to secure their support for the company's planned dissolution.

NovaBay Pharmaceuticals has engaged Lucid Capital Markets to explore strategic alternatives, including a potential business combination, as it faces uncertainty regarding stockholder approval for its proposed liquidation and dissolution.

NovaBay Pharmaceuticals' stockholders did not approve the proposed liquidation and dissolution plan at a recent meeting, prompting the company to schedule a new special meeting for another vote.

NovaBay Pharmaceuticals has finalized the sale of its Avenova eyecare business for $11.5 million and has adjourned its special stockholder meeting to allow more time for voting on the company's planned liquidation.

NovaBay Pharmaceuticals has extended CEO Justin M. Hall's employment agreement through December 31, 2025, via a third amendment to his existing contract.

NovaBay Pharmaceuticals has sold its wound care trademarks and related inventory to Phase One Health for a total of $626,000.

NovaBay Pharmaceuticals has further adjourned its special meeting of stockholders due to a lack of sufficient votes to approve the sale of its assets and subsequent dissolution of the company.

NovaBay Pharmaceuticals has adjourned its special meeting of stockholders due to insufficient votes to approve the sale of its assets and the company's dissolution, and will reconvene on December 18, 2024.